A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

NCT07728383 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity & Overweight

Interventions

DRUG: Semaglutide 6 mg liquid emulsion formulation
DRUG: Wegovy® (semaglutide) Tablet
DRUG: Placebo liquid emulsion formulation

Sponsor

Gila Therapeutics, Inc.